Sign In
Buy RGEN
$149.78
+2.72 (+1.85%)
At Close: Aug 04, 2026
Repligen (RGEN) Promotes CCO, Shares Fall on Leadership Change
12:45pm, Friday, 14'th Jun 2024
Repligen (RGEN) appoints Olivier Loeillot as the company's new president and chief executive officer, effective from Sep 1, 2024. Stock falls on the news.
Repligen Announces CEO Transition Plan
07:00am, Thursday, 13'th Jun 2024
Tony J. Hunt to Transition from Chief Executive Officer to Executive Chair, Olivier Loeillot Appointed to Role of President and Chief Executive Officer, Effective September 1, 2024 Tony J. Hunt to Tra
ST. PAUL, Minn. & WALTHAM, Mass.--(BUSINESS WIRE)--Ecolab today announced that its Purolite resin business, together with Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioproc
Repligen Corporation to Present at Upcoming June Investor Conferences
07:30am, Wednesday, 22'nd May 2024
WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting
Repligen Corporation to Present at Upcoming May Investor Conferences
07:30am, Tuesday, 07'th May 2024
WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participati
Repligen (RGEN) Q1 Earnings Miss, Revenues Beat Estimates
12:26pm, Thursday, 02'nd May 2024
Repligen's (RGEN) first-quarter 2024 earnings miss estimates while revenues beat the same.
Repligen (RGEN) Misses Q1 Earnings Estimates
09:51am, Wednesday, 01'st May 2024
Repligen (RGEN) came out with quarterly earnings of $0.28 per share, missing the Zacks Consensus Estimate of $0.29 per share. This compares to earnings of $0.64 per share a year ago.
Repligen Reports First Quarter 2024 Financial Results
07:30am, Wednesday, 01'st May 2024
WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fi
Repligen to Report First Quarter 2024 Financial Results
07:30am, Wednesday, 17'th Apr 2024
Webcast and Conference Call to Be Held Wednesday, May 1, 2024, at 8:30 a.m. ET Webcast and Conference Call to Be Held Wednesday, May 1, 2024, at 8:30 a.m. ET
Repligen Appoints Maggie A. Pax to Board of Directors
07:30am, Tuesday, 19'th Mar 2024
WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax. This
PBYI vs. RGEN: Which Stock Is the Better Value Option?
12:46pm, Monday, 04'th Mar 2024
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Puma Biotech (PBYI) and Repligen (RGEN). But which of these two companies is the best op
Repligen (RGEN) Stock Down on Q4 Earnings Miss, Revenues Fall Y/Y
11:41am, Thursday, 22'nd Feb 2024
Repligen's (RGEN) fourth-quarter 2023 earnings miss estimates and decline year over year. Stock declines.
Repligen Corporation (RGEN) Q4 2023 Earnings Call Transcript
02:35pm, Wednesday, 21'st Feb 2024
Repligen Corporation (RGEN) Q4 2023 Earnings Call Transcript
Repligen (RGEN) Lags Q4 Earnings and Revenue Estimates
09:46am, Wednesday, 21'st Feb 2024
Repligen (RGEN) came out with quarterly earnings of $0.33 per share, missing the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.68 per share a year ago.
Repligen Reports Fourth Quarter and Full Year 2023 Financial Results
07:30am, Wednesday, 21'st Feb 2024
WALTHAM, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its f
